Head-to-head evidence
CX11 vs semaglutide
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Obesity
Shared mechanism: GLP-1 receptor · full Obesity pipeline
CX11
Developed by Corxel Pharmaceuticals
NCT07011797 · Phase 2 · completed
In this randomized, double-blind, placebo-controlled Phase 2 trial, 250 adults with obesity were assigned to CX11 at several doses or placebo for 26 weeks, with follow-up to 36 weeks. The company reported that the trial's weight-loss primary endpoints were met, with weight loss reaching up to 11.5% by week 36 and continuing without a plateau; gastrointestinal side effects were the most common safety finding.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Next expected readout: March 2027 · NCT07652047 (registry estimate)
semaglutide · Wegovy / Ozempic / Rybelsus
Marketed by Novo Nordisk
NCT03548935 · Phase 3 · completed
This was a randomized, quadruple-blind, placebo-controlled trial of 1,961 participants. At week 68, mean body-weight change was -15.6% with semaglutide versus -2.8% with placebo, and the primary comparison was statistically significant (p<0.0001), supporting strong evidence for this clinical weight-loss endpoint.
Next expected readout: October 2026 · NCT07505303 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: CX11's landscape · semaglutide's landscape